Business Wire

Senioradom & Sigfox Sign New Partnership to Be Developed in Chengdu, China


Today, telecare company Senioradom and Sigfox, the world’s leading IoT connectivity service, signed a strategic agreement in the presence of both the French President Emmanuel Macron and Chinese President Xi Jinping to begin their deployment in the Chinese market.

This press release features multimedia. View the full release here:

Sigfox CEO Ludovic Le Moan, French President Emmanuel Macron and Chinese President Xi Jinping (Photo ...

Sigfox CEO Ludovic Le Moan, French President Emmanuel Macron and Chinese President Xi Jinping (Photo: Business Wire)

The Chengdu High-Tech Industrial Development Zone has committed to an investment of almost €300M to deploy the solution in China’s 20 biggest cities, following a one-year, 1500-person trial, beginning in 2018 in the city of Chengdu.

An innovative and revolutionary solution
Senioradom and Sigfox have developed a telecare solution made up of different movement sensors and door opening detection, as well as an alert and geo-localisation necklace. The solution has been designed to automatically detect any potential behavioural anomalies due to a fall, a person feeling faint or a deteriorating mental condition such as Alzheimer’s. Thanks to the autolearning algorithms developed by Senioradom, which have been operating successfully in France for the past 3 years, together with Sigfox’s technology that allows the transmission of data at a very low cost and with minimum energy use, this innovative solution will allow different cities in China to better protect their elderly populations by anticipating risks and acting faster in emergencies.

A profitable market yet to be developed
China currently has 200 million senior citizens, yet no telecare solution has, until now, been developed. A rural exodus of the active population towards major cities and the low income of a large proportion of the elderly population, as well as a lack of hospitals and doctors, has pushed China to find affordable solutions that are quick to deploy, to help the Chinese administration face this significant social challenge. Thanks to this partnership, hospitalisation and medical costs will be significantly reduced due to the prevention of dangerous situations.

“After a year of work with the French and Chinese authorities and our partner Sigfox, we are proud to see that French expertise can attract the interest of such a big nation, one that is taking a pragmatic, preventative approach to the issue of elderly dependence”, said Thierry Roussel, cofounder of Senioradom. “We also wish to thank the tireless work of the French Embassy in Beijing and the Chinese Embassy in France, the BPI, Business France and our Ministries, which have been involved throughout the negotiations. For Senioradom, which launched 5 years ago, this is a great recognition of our work and a perfect platform for our international development”.

Ludovic Le Moan, CEO of Sigfox stated: “I am honoured to sign this agreement today, as it is the product of many months of hard work, both by our teams and those of our partner Senioradom. We are grateful to the French authorities for their support, without which this agreement would not have been possible. This is a key milestone for Sigfox and its development in China, where the IoT industry has incredible untapped potential. This partnership is just the first step towards a bigger presence in the region and shows that Sigfox can provide innovative solutions with the ability to radically change the country’s IoT market”.

About Sigfox
Sigfox is the world’s leading provider of connectivity for the Internet of Things (IoT). The company has built a global network to connect billions of devices to the Internet while consuming as little energy as possible, as simply as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption, and global scalability.
Today, the network is present in 43 countries and on track to cover 60 by 2018. With millions of objects connected and a rapidly growing partner ecosystem, Sigfox empowers companies to move their business model towards more digital services. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in Labège near Toulouse, France’s “IoT Valley”. Sigfox also has offices in Paris, Madrid, Munich, Boston, San Francisco, Dubai, Singapore and Tokyo.

About Senioradom
Created in 2012, Senioradom has developed a telecare solution designed to automatically detect behavioural anomalies due to a fall, a person feeling faint or a deteriorating mental condition such as Alzheimer’s. At the crossroads between IoT and AI, the solution is supported by a diverse set of investors, all of whom are committed to creating innovative solutions to meet the challenges facing senior citizens.

Contact information

Guillaume BINOCHE
Director of Public Affairs
Public Relations Manager
For more information:
Christophe GOMBAULT
For more information:

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme